Halozyme price target raised to $72 from $70 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $72 from $70 and keeps a Buy rating on the shares following the Q4 report. The company reported a sales beat driven by a jump in royalty revenues, the analyst tells investors in a research note. The firm says the Enhanze business “remains the crux” of its investment thesis.